 BOSTON, Oct. 7, 2021 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq: MITO, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new promising data from a study evaluating the effects of SBT-272 in a murine model of amyotrophic lateral sclerosis ALS. The data were presented at the virtual 2021 Annual Northeast Amyotrophic Lateral Sclerosis NEALS Meeting held October 6-7, 2021. 